摘要
目的评价重组人尿激酶原(rhPro-UK)治疗老年急性ST段抬高型心肌梗死(STEMI)患者的临床效果及安全性。方法40例STEMI患者,按年龄分为老年1组(≥75岁,<85岁,8例)、老年2组(≥65岁,<75岁,12例)及对照组(<65岁,20例)。三组患者均接受rhPro-UK溶栓治疗。比较三组溶栓效果[胸痛缓解时间、ST段回落≥50%时间、肌酸激酶同工酶(CK-MB)酶峰时间及临床再通情况]、出血及主要心血管不良事件(MACE)发生情况。结果三组胸痛缓解时间、ST段回落≥50%时间、CK-MB酶峰时间及临床再通率比较,差异均无统计学意义(P>0.05)。老年1组和老年2组轻度出血发生率均为25.00%,均高于对照组的15.00%,但差异无统计学意义(P>0.05)。老年1组MACE发生率为12.50%,老年2组为25.00%,对照组为15.00%,三组MACE发生率比较,差异无统计学意义(P>0.05)。结论rhPro-UK治疗老年STEMI患者有效性高、安全性好。
Objective To evaluate the clinical effect and safety of recombinant human prourokinase(rhPro-UK)in elderly patients with acute ST-segment elevation myocardial infarction(STEMI).Methods A total of 40 patients with STEMI were divided by age into elderly group 1(≥75 years,<85 years,8 cases),elderly group 2(≥65 years,<75 years,12 cases)and control group(<65 years,20 cases).Patients in all three groups received rhPro-UK thrombolytic therapy.The thrombolytic effect[time to relief of chest pain,time to≥50%STsegment resolution,time to peak creatine kinase isoenzyme(CK-MB)and clinical recanalization],bleeding and occurrence of major adverse cardiovascular events(MACE)of the three groups were compared.Results There was no statistically significant difference in time to relief of chest pain,time to≥50%ST-segment resolution,time to peak creatine kinase isoenzyme(CK-MB)and clinical recanalization among the three groups(P>0.05).The incidence of mild bleeding was 25.00%in both elderly group 1 and elderly group 2,which was higher than 15.00%in the control group,but the difference was not statistically significant(P>0.05).The incidence of MACE was 12.50%in the elderly group 1,25.00%in the elderly group 2,and 15.00%in the control group.There was no statistically significant difference in incidence of MACE among the three groups(P>0.05).Conclusion rhPro-UK is highly effective and safe in the treatment of elderly STEMI patients.
作者
农耀明
雷灵亮
张长海
贝俊杰
赵丽霞
NONG Yao-ming;LEI Ling-liang;ZHANG Chang-hai(Department of Critical Care,Guangxi Armed Police Corps Hospital,Nanning 530003,China)
出处
《中国实用医药》
2021年第34期16-19,共4页
China Practical Medicine
关键词
重组人尿激酶原
急性ST段抬高型心肌梗死
溶栓
老年患者
Recombinant human prourokinase
Acute ST-segment elevation myocardial infarction
Thrombolysis
Elderly patients
